Obesity is a critical risk factor for hepatocellular carcinoma (HCC). However, it remains unknown whether inhibition of de novo lipid biosynthesis can suppress HCC. In this study, we blocked the sterol regulatory element-binding protein (SREBP) pathway, one of the key determinants of lipid homeostasis, by ablating 78-kDa cell-surface glycoprotein or SREBP cleavage-activating protein in hepatocytes, as well as by administering a chemical compound called betulin. We found that either genetically or pharmacologically inhibiting the SREBP pathway dramatically reduced diethylnitrosamineinduced HCC progression by down-regulating tumor-promoting cytokines, including interleukin (IL)-6, tumor necrosis factor alpha, and IL-1b. Conclusion: Inhibition of de novo lipid biosynthesis by suppressing the SREBP pathway prevents HCC. This study identifies a previously underappreciated role of the SREBP pathway in HCC and suggests a novel metabolic strategy to control liver cancer. (HEPATOLOGY 2017;65:1936-1947).
H epatocellular carcinoma (HCC) is among the most prevalent cancers, affecting more than half a million individuals worldwide per year. (1) In addition to hepatitis B and C viruses, (2) overweight and obesity are emerging risk factors for HCC. (3) This obesity-induced HCC development involves elevated levels of tumor necrosis factor-a (TNF-a) and interleukin (IL)-6, which leads to enhanced inflammatory responses in liver. (4) In addition, it has been reported that HCC development is associated with inflammation. (5, 6) It is noteworthy, however, that the liver is the epicenter of lipid metabolism where most cholesterol and fatty acids (FAs) are synthesized. Whether lipid biosynthesis augments the risk of HCC has yet to be determined.
Sterol regulatory element-binding protein (SREBP) is a critical regulator governing lipid homeostasis. (7) SREBPs are first synthesized as inactive precursors and form a complex with SREBP cleavage-activating protein (SCAP). When cellular sterol level increases, the SCAP-SREBP complex is retained by insulininduced gene (Insig) 1/2 proteins in the endoplasmic reticulum (ER). When cellular sterol level declines, Abbreviations: ACC, acetyl-CoA carboxylase; DEN, diethylnitrosamine; EDTA, ethylenediaminetetraactic acid; EGTA, ethyleneglycoltetraacetic acid; ER, endoplasmic reticulum; ERAD, ER-associated degradation; FA, fatty acid; FASN, fatty acid synthase; gp78, 78-kDa cell-surface glycoprotein; GTT, glucose tolerance test; HCC, hepatocellular carcinoma; H&E, hematoxylin-eosin; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HMGCS, HMG-CoA synthase; IL, interleukin; Insig, insulin-induced gene; ITT, insulin tolerance test; KAI1, kangai-1; LDLR, low-density lipoprotein receptor; P, postnatal day; SCAP, SREBP cleavage-activating protein; SCD-1, stearoyl CoA desaturase-1; SDS, sodium dodecyl sulfate; SREBP, sterol regulatory element-binding protein; TNF-a, tumor necrosis factor alpha; UPR, unfolded protein response; WT, wild type.
however, SCAP dissociates from Insig1/2 and escorts SREBPs to the Golgi apparatus. SREBPs then undergo protease cleavages to liberate the active N-terminal transcriptional domain, which enters the nucleus and activates genes for lipid biosynthesis and uptake. In addition to sterol fluctuations, SREBP proteolysis can also be regulated by 78-kDa cell-surface glycoprotein (gp78), an ER membrane-anchored ubiquitin ligase mediating Insig1/2 degradation. (8, 9) Depletion of gp78 in mouse liver increases Insig1/2 levels, blunts lipid biosynthesis, and reduces the susceptibility to diet-and aged-induced obesity and glucose intolerance. (8) Furthermore, betulin, a pentacyclic triterpene abundant in birch bark, has been found to bind and promote the interaction of SCAP with Insig1/2, thus protecting against diet-induced obesity and atherosclerotic plaques in mice. (10) An up-regulation of the SREBP pathway has been reported in the progression of androgen-independent prostate cancer and glioblastoma (11, 12) and increasing FA synthesis (which is regulated by the SREBP pathway) enhances HCC in patients, (13) suggesting that the SREBP pathway may play a role in cancer. In the present study, we aimed to investigate the contribution of the SREBP pathway to HCC development. Diethylnitrosamine (DEN) is a widely used HCC inducer, and DEN-induced HCC resembles human liver cancer. (14, 15) By administering a single dose of DEN into liver-specific gp78 (L-gp78
) and SCAP (L-SCAP
2/2
) knockout mice, we demonstrated that both models with inhibited SREBP pathways and reduced lipid biogenesis were less susceptible to DENinduced hepatocarcinogenesis. We further found that expression of inflammatory cytokines was dramatically suppressed upon gp78 or SCAP ablation. Furthermore, betulin treatment effectively attenuated inflammatory responses and HCC development in C57BL/6J mice challenged with DEN. These results suggest that inhibition of the SREBP pathway may be used as a potential therapeutic strategy to treat HCC.
Materials and Methods

ANIMALS AND TREATMENTS
Male C57BL/6J mice were obtained from SLAC (Shanghai, China). Liver-specific gp78 knockout and SCAP knockout mice were generated by crossing gp78 f/f mice (8) and SCAP f/f mice (16) with transgenic C57BL/6J mice expressing Cre recombinase driven by albumin promoter (Nanjing Biomedical Research Institute of Nanjing University, Nanjing, China). To ensure genetic homogeneity, L-gp78 2/2 and L-SCAP 2/2 mice were both backcrossed to C57BL/6J mice for at least 10 generations. Mice had access to standard chow diet and water ad libitum, maintained in a pathogen-free environment in single-ventilated cages, and kept on a 12-hour light/dark schedule. All animals were used in accord with the guidelines of the Institutional Animal Care and Use Committee of the Shanghai Institutes for Biological Sciences.
To induce liver tumors, a single dose of DEN (40 mg/kg body weight; Sigma-Aldrich, St Louis, MO, USA) was injected intraperitoneally at postnatal day (P) 14 (P14). To measure DEN-induced inflammation, a single dose of DEN (100 mg/kg body weight) was injected intraperitoneally into 4-week-old mice. To evaluate the effect of betulin on DEN-induced inflammation, 3-week-old C57BL/6J mice were gavaged with saline or betulin (100 mg/kg body weight/ day) once-daily for 10 consecutive days followed by a single intraperitoneal injection of DEN (100 mg/kg body weight). To evaluate the effect of betulin on DEN-induced HCC, 2-week-old C57BL/6J mice were injected intraperitoneally with DEN (40 mg/kg body weight). One month later, mice were fed with chow diet supplemented with or without betulin (50 mg/kg body weight /day) for 6 additional months.
The two-thirds partial hepatectomy was performed as described. (17) Four days later, mice were sacrificed and the remnant lobes were harvested.
BLOOD AND LIVER CHEMISTRY
Serum glucose, total cholesterol, and total triglyceride levels were determined according to the manufacturers' instructions (KINGHAWK, Beijing, China). Free FA was enzymatically measured using an NEFA C Test Kit (Wako Diagnostics, Richmond, VA, USA). Serum levels of insulin, IL-6, and TNF-a were measured using an enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA).
GLUCOSE TOLERANCE AND INSULIN TOLERANCE TESTS
Mice were fasted overnight (glucose tolerance test; GTT) or for 4 hours (insulin tolerance test; ITT) in advance. D-glucose solution (2 g/kg body weight; GTT) or insulin (0.75 U/kg body weight; ITT) was injected intraperitoneally into mice. Tail blood glucose levels were measured at 0, 30, 60, and 120 minutes after challenge using the Onetouch Ultra blood glucose monitoring system (LifeScan, Milpitas, CA, USA).
RT-qPCR
Total RNA was extracted from mouse tissues using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of RNA were pooled and subjected to reverse transcription with oligo-dT followed by quantitative real-time PCR using target-specific primers in the Stratagene Mx30005P Q-PCR Systems. All reactions were prepared in triplicate, and the relative amounts of mRNAs were calculated using the comparative threshold cycle method. Mouse cyclophilin was used as the control. Values show the amount of mRNA relative to control sample, which is arbitrarily defined as 1. The primer sequences of IL-6, TNF-a, and IL-1b, (18) as well as lipogenic genes, (10) have all been described.
HISTOLOGY
Mouse tissues were fixed with 4% paraformaldehyde overnight, embedded in paraffin, and cut into 3-lm sections using a microtome (Leica RM2235; Leica Microsystems). Sections were then deparaffined and stained with hematoxylin-eosin (H&E; SigmaAldrich) for pathological evaluation. Liver tumors were identified and quantified on sections. Lysates were centrifuged at 1,000g for 10 minutes at 48C, and pellet was resuspended in 0.2 mL of buffer C (20 mM of HEPES/KOH [pH 7.6], 2.5% glycerol, 1.5 mM of MgCl 2 , 0.42 M of NaCl, 1 mM of EDTA, and 1 mM of EGTA) supplemented with protease inhibitors. Suspension was then rotated for 1 hour at 48C and centrifuged at 100,000g for 30 minutes at 48C. Supernatant from this spin was used as the nuclear extract. For the membrane fraction preparation, supernatant from the original 1,000g spin was centrifuged at 100,000g for 30 minutes at 48C. Pellet was then dissolved in 0.2 mL of sodium dodecyl sulfate (SDS) lysis buffer (10 mM of Tris-HCl [pH 6.8], 100 mM of NaCl, 1% SDS, 1 mM of EDTA, and 1 mM of EGTA). Next, 150 lL of the above prepared fraction were mixed with an equal volume of buffer containing 62.5 mM of Tris-HCl (pH 6.8), 15% SDS, 8 M of urea, 10% glycerol, and 100 mM of dithiothreitol, followed by the addition of 100 lL of 43 SDS loading buffer. Samples were pooled, incubated at 378C for 30 minutes, and then subjected to SDS/polyacrylamide gel electrophoresis. After electrophoresis, samples were transferred to nitrocellulose membranes and subjected to immunoblotting analysis with the Tanon 5200 chemiluminescent imaging system (Tanon Science and Technology, Shanghai, China).
KUPFFER CELL ISOLATION
Kupffer cells were isolated from 6-to 8-week-old male mice by collagenase (Blendzyme 2 and 3; Roche, Indianapolis, IN, USA) digestion, and then they were subjected to centrifugation on a Percoll (Sigma-Aldrich) gradient. (19) In brief, the liver was perfused with calcium-free solution and then digested with a collagenase perfusion. Dispersed cells were released from the isolated liver, and hepatocytes were collected after a brief 50g centrifugation. Pellets were hepatocytes, and the supernatant were nonparenchymal cells and were centrifuged on a Percoll gradient at 1,350g for 10 minutes. Kupffer cells and endothelia cells fraction were isolated. After being plated in tissue culture dishes, and washed after 1 hour to remove nonadherent cells, the highpurity Kupffer cells were left in a culture dish. Kupffer cells were stained with F4/80 antibody (sc59171; Santa Cruz Biotechnology, Dallas, TX, USA) and observed with a fluorescence microscope. Necrotic hepatocytes were prepared by freezing (2808C) and thawing (room temperature) the isolated hepatocytes for at least three times. Lipopolysaccharides (Escherichia coli; SigmaAldrich) or filtered 10 6 necrotic hepatocytes/mL were incubated with Kupffer cells. The RNA was then isolated with TRIzol (Thermo Fisher Scientific) and qPCR was performed for IL-6 and IL-1b.
STATISTICAL ANALYSIS
Values are presented as mean 6 SD. comparison between two groups. P < 0.05 was considered statistically significant.
Results
ABLATION OF GP78 IN THE LIVER INHIBITS DEN-INDUCED HEPATOCARCINOGENESIS
To elucidate whether de novo lipid biosynthesis has any effect on DEN-induced HCC development, we administered a single dose of DEN (40 mg/kg) intraperitoneally at P14 to L-gp78 2/2 mice, a well-characterized model with an attenuated SREBP pathway and decreased lipid biosynthesis, (8) and wild-type (WT) controls. We then sacrificed the mice and identified and quantified the liver tumor load at the age of 10 months. We detected significantly fewer (Fig. 1A,B) and smaller (Fig. 1A,C) HCCs in DEN-treated L-gp78 2/2 mice than those in the control group. A more than 40% reduction in the incidence of tumor development upon DEN treatment was also observed in L-gp78 2/2 mice (Fig. 1D) . Given that tumorigenesis is characterized by active cell division, we evaluated the number of cells immunopositive for Ki67, a general proliferation marker, in livers of DEN-treated animals. L-gp78 2/2 mice exhibited a dramatic 75.4% decrease in Ki67 labeling relative to control mice (Fig.  1E) . Taken together, these results show that L-gp78 2/2 mice are resistant to DEN-induced hepatocarcinogenesis.
In DEN-treated WT mice, expression levels of gp78 and SCAP were similar between tumor and nontumor tissues. However, the SREBP1a, 1c, and SREBP2 mRNAs were significantly increased in tumor versus nontumor tissues. Consistently, expression levels of SREBP target genes, including fatty acid synthase (FASN), acetyl CoA carboxylase (ACC), HMG-CoA reductase (HMGCR), and HMG-CoA synthase (HMGCS), were also significantly elevated in tumor tissues (Supporting Fig. S1A ). To confirm that HCCbearing L-gp78 2/2 mice indeed had lower lipid levels, we examined gene expression profiling of tumor tissues by qPCR. Expression levels of SREBP-1a, SREBP-1c, and SREBP-2 were all decreased in DEN-treated Lgp78 2/-mice (Fig. 1F) . Consistently, SREBP target genes, including those involved in cholesterol uptake and synthesis, including low-density lipoprotein receptor (LDLR), HMGCR, and HMGCS, as well as those in FA synthesis, including FASN, ACC, and stearoyl CoA desaturase-1 (SCD-1), were all significantly down-regulated in DEN-treated L-gp78 2/2 mice.
We also measured the metabolic parameters of DEN-injected mice at the age of 10 months (Supporting Fig. S1B ). Plasma cholesterol, triglycerides, and free FAs of L-gp78 2/2 mice were 35%, 32%, and 8% lower in control littermates, respectively. Plasma glucose and insulin levels were 36% and 69% lower in L-gp78 2/2 mice, respectively. Moreover, liver cholesterol and triglycerides of L-gp78 2/2 mice were significantly decreased. Furthermore, glucose tolerance and insulin resistance in DEN-treated L-gp78 2/2 mice was significantly improved as measured by the GTT and ITT (Supporting Fig. S1C,D) . Together, these results are in line with our previous findings, (8) suggesting that knockout of gp78 in the liver favors lipid and glucose metabolism regardless of DEN treatment. We therefore conclude that de novo lipid biosynthesis may correlate with hepatocarcinogenesis.
LIVER-SPECIFIC DEFICIENCY OF SCAP DECREASES DEN-INDUCED HEPATOCARCINOGENESIS
SCAP is critically involved in the translocation and proteolytic processing of SREBPs. (20, 21) Conditionally knocking out SCAP in mouse liver decreases the biosynthesis of both cholesterol and FAs, (16) serving as an independent model to evaluate the role of lipid biosynthesis in HCC. Liver-specific SCAP knockout (L-SCAP 2/2 ) mice and WT controls were subjected to DEN injection as described above, followed by tumor examination 10 months postinjection. Similar to what we observed in L-gp78 2/2 mice, the tumor number, maximal size, and incidence were all remarkably reduced in L-SCAP 2/2 mice compared to controls ( Fig. 2A-D) . In addition, the number of Ki67 1 cells in L-SCAP 2/2 livers was around 25% of that in control livers (Fig. 2E) . These results indicate that SCAP deficiency in the liver protects against the oncogenic effect of DEN.
To investigate whether DEN-treated L-SCAP 2/2 mice exhibited decreased lipid biogenesis, we measured expression of critical lipogenic genes in liver tumors by qPCR. Compared to littermate controls, mRNA levels of LDLR, HMGCR, HMGCS, FAS, SCD-1, ACC, SREBP1c, and SREBP2 were all significantly downregulated in DEN-treated L-SCAP 2/2 mice, whereas those of SREBP1a and Insig2 were moderately reduced (Fig. 2F) . In addition, L-SCAP 2/2 mice displayed significantly less plasma insulin, cholesterol, triglycerides, and free FAs, as well as slightly declined plasma glucose (Supporting Fig. S2A ). Moreover, liver cholesterol and triglycerides of L-SCAP 2/2 mice were significantly decreased. Furthermore, GTT and ITT analyses showed improved glucose tolerance and insulin sensitivity in DEN-treated L-SCAP 2/2 mice, although the latter was not statistically different from that of littermate controls (Supporting Fig. S2B,C) . In summary, these data suggest that inhibition of the SREBP pathway by ablating SCAP suppresses HCC development.
INFLAMMATORY RESPONSE IS ATTENUATED UPON GP78 OR SCAP DEPLETION
We next sought to unravel the mechanism how de novo lipid synthesis contributes to HCC development. Given that lipids are required for cell growth and proliferation, we performed a two-thirds partial hepatectomy and examined the ratio of liver mass per body weight 4 days postsurgery (Fig. 3A) . Surprisingly, no difference was detected among L-gp78 2/2 , L-SCAP 2/2 and control mice (Fig. 3B) , suggesting that inhibiting the SREBP pathway does not affect liver regeneration and hepatocyte proliferation. The cells may acquire lipids from blood.
Given the fact that hepatic inflammatory cytokines, such as TNF-a and IL-6, could increase the risk of HCC, (4) we next investigated whether HCC-resistant L-gp78 2/2 and L-SCAP 2/2 mice had reduced levels of inflammatory factors. Compared to control mice, expression levels of TNF-a, IL-1b, and IL-6 were significantly lower in L-gp78 2/2 and L-SCAP 2/2 mice (Fig. 4A) . In addition, serum levels of IL-6 and TNFa were slightly decreased in L-gp78 2/2 mice, but significantly declined in L-SCAP 2/2 mice (Fig. 4B ). We next compared acute inflammatory responses of L-gp78
, L-SCAP 2/2 and control mice receiving a single dose of 100 mg/kg of DEN. Notably, the time-dependent elevation in mRNA levels of IL-1b and IL-6 observed in the control group was severely blunted in L-gp78 2/2 and L-SCAP 2/2 mice (Fig.  4C,D) . We also investigated the role of ER stress given that it has been implicated in HCC development. (22) In WT mice, tumor tissue showed significantly higher ER stress compared with nontumor tissue, as indicated by the expression levels of binding immunoglobulin protein and C/EBP homologous protein genes (Supporting Fig. S3A ). DEN treatment increased ER stress in mice livers; however, ER stress was significantly less in L-SCAP 2/2 mice than in WT mice (Supporting Fig. S3B ). Taken together, these data suggest that inflammatory response and ER stress are suppressed following SREBP inhibition, which may protect against DENinduced hepatocarcinogenesis.
INHIBITION OF THE SREBP PATHWAY BY BETULIN AMELIORATES DEN-INDUCED HCC
Betulin effectively inhibits SREBP processing and down-regulates lipid biosynthesis. (10) We therefore hypothesize that betulin may ameliorate DENinduced hepatocarcinogenesis through blocking the SCAP/SREBP pathway. To test this hypothesis, C57BL/6J mice were gavaged with saline or betulin at a dose of 100 mg/kg/day for 10 consecutive days followed by a single intraperitoneal injection of DEN at a dose of 100 mg/kg. As expected, cleavage of SREBP was specifically inhibited by betulin (Fig. 5A) . At 24 and 72 hours after DEN administration, we observed significantly lower expression of SREBP target genes, including HMGCR and FASN (Fig. 5B) , as well as inflammatory cytokines such as IL-1b and IL-6 (Fig.  5C ), in the betulin-treated group compared to saline controls. These results suggest that betulin can inhibit DEN-induced inflammation.
To further address whether betulin has any beneficial effects on HCC formation, C57BL/6J mice were injected intraperitoneally with DEN at a dose of 40 mg/kg at P14. One month later, mice were fed with chow diet supplemented with or without betulin (50 mg/kg/day) for 6 additional months. Strikingly, betulin-treated mice exhibited a 71% and 76% reduction in the number and maximal size of tumors in liver relative to saline controls, respectively (Fig. 6A-C) . Incidence of DEN-induced tumor development was also decreased by 18% following betulin treatment (Fig.  6D) . In addition, expression levels of genes involved in cholesterol metabolism, FA metabolism, and inflammation were all significantly down-regulated in betulintreated mice (Fig. 6E) . Betulin also decreased serum levels of IL-6 and TNF-a by 40% and 56%, respectively (Fig. 6F) . Of all the metabolic parameters evaluated, levels of plasma glucose, cholesterol, and triglycerides were all significantly down-regulated in betulin-treated mice (Fig. 6G) . Together, these results indicate that betulin can inhibit HCC formation through suppressing inflammatory responses.
Discussion
In this study, we used liver-specific gp78-or SCAPdeficient mice and betulin-treated C57BL/6J mice to evaluate the role of the SREBP pathway in HCC development. This study provided compelling evidence showing that inhibiting the SREBP pathway could decrease HCC and suggested a novel metabolic strategy to control HCC. gp78 is a major E3 ubiquitin ligase in the liver mediating degradation of HMGCR in response to high levels of sterol. (23) It also promotes degradation of Insig1/2 that would otherwise sequester the SCAP/SREBP complex in the ER from further proteolysis and maturation. Therefore, knockout of gp78 imposes a potential check on lipid metabolism. Our previous findings have shown that the effect of gp78 ablation on SREBP inhibition outweighs that on HMGCR stabilization, resulting in a net decrease in lipid biosynthesis. (8) In addition, although gp78 may also mediate ER-associated degradation (ERAD) of other proteins such as CD3-d, (24) apolipoprotein B-100, (25) and kangai-1 (KAI1), (26) the unfolded protein response (UPR) is not dramatically elevated in gp78-deficient liver, (8) suggesting that gp78 is primarily involved in lipid biosynthesis rather than the ERAD pathway. The L-gp78 2/2 mouse line is therefore a suitable genetic tool to explore the function of lipid biosynthesis in HCC development. On the other hand, SCAP is an ER-embedded protein that directly binds and mediates the exit of SREBPs out of the ER. Liver-specific SCAP-deficient mice show an 80% reduction in the basal rates of cholesterol and FA synthesis in the liver, owing to the downregulation of mRNAs encoding multiple biosynthetic enzymes. (16, 27) Alternatively, the administration of betulin, which binds SCAP and stimulates SCAPInsig interaction, down-regulates expression of SREBP target genes as well as lipid levels in cultured cells and mice. (10) These three models are therefore utilized to elucidate the effect of lipid biosynthesis on HCC development. Here, we demonstrate that inhibition of the SREBP pathway prevents DENinduced tumorigenesis and associated inflammation. Compared to their littermate controls, L-gp78
and L-SCAP 2/2 mice are less susceptible to the tumor inducer, DEN, and display attenuated inflammatory responses upon DEN treatment. Moreover, betulin treatment on C57BL/6J mice with DEN exposure ameliorates liver inflammation and HCC progression. We therefore conclude that lipid biosynthesis plays a crucial role in regulating HCC initiation and development and that betulin can be used as an anti-tumor compound through targeting the SREBP pathway. In fact, gp78 has been strongly implicated in the initiation and progression of various cancers. An increase in gp78 expression with a concomitant reduction in E-cadherin defines a high risk for bladder carcinomas. (28, 29) Enhanced gp78 expression may increase cellular mobility and even produce tumors in nude mice. (30) Level of gp78 expression highly correlates with histopathological stage and grade of tumor penetration in human gastric cancer. (31) Suppression of gp78, by increasing the abundance of transmembrane metastasis suppressor KAI1, limits the metastatic potential of sarcoma cells. (26) These studies are in support of our conclusions that gp78 may function as a tumor-promoting factor. In contrast to these notions, however, mice carrying murine mammary tumor virus long terminal repeat-driven gp78 transgene display no signs of mammary tumorigenesis over a period of 18 months after birth. (32) In addition, spontaneous HCC accompanied by increased hepatic inflammation, steatosis, and fibrosis has been detected in aged gp78 knockout mice. (33) The discrepancies between these results and ours can be explained by differences in tumor types and stages, knockout approaches (global vs. liver-specific), and cancer-inducing methods (aging vs. DEN). The specific roles and mechanisms of gp78 on cancer development under different circumstances require further investigation.
There are also numerous studies showing that SCAP and SREBP are closely related to tumor development. Genetically silencing SCAP reduces the viability of breast cancer cells. (34) Pharmacological and genetic inhibition of SCAP significantly attenuates U87 xenograft tumor growth. (35) Furthermore, expression of SREBP-1 is substantially increased in aggressive human prostate and HCC tissues. (36, 37) These findings are line with our results, both of which suggest that SCAP may function as a tumor promoter, and that inhibition of the SREBP pathway, such as by betulin, might be a promising strategy to control tumor progression.
Given that inflammatory response and ER stress have been reported to modulate HCC development, (4, 22) we investigated expression of inflammation and UPR genes. The results showed that inflammation and ER stress were reduced in mouse livers with SREBP inhibition. We speculate that inhibition of lipid biosynthesis represses inflammatory responses and ER stress, which further limits liver tumor incidence and growth. Liver injury, hepatocyte damage, and ER stress can be induced by carcinogens such as DEN. In addition, ER stress can increase lipogenesis and oxidative stress, which make hepatocytes prone to cell death. (22) The dead hepatocytes then release proinflamatory mediators, including IL-1a (38) and lipids, (39, 40) to activate liver Kupffer cells to produce more cytokines (41) and growth factors, including IL-1b, IL-6, and TNFa. The debris of hepatocytes did increase expression levels of IL-1b and IL-6 in Kupffer cells (Supporting Fig. S4 ). This inflammatory microenvironment is essential for expansion of mutated hepatocytes. The accumulation of mutated hepatocytes subsequently results in HCC development. However, inhibition of the SREBP pathway leads to reduced de novo lipid biosynthesis, which decreases levels of proinflamatory lipids and suppresses inflammation and ER stress. Thus, HCC progress is inhibited.
In conclusion, our study shows that the SREBP pathway plays an important role in HCC. Inhibiting this pathway could be a promising strategy to control HCC.
